We are a global innovation-driven biopharmaceutical company specialising in the discovery, development, manufacturing and marketing of prescription medicines that make a meaningful difference in healthcare.
Science and patients are at the heart of everything we do, and our skills and resources are concentrated on those therapy areas where we believe we can make the most difference. We focus primarily on cancer, cardiovascular/metabolic disease and respiratory/inflammation/autoimmunity. Alongside this, we remain active in infection and neuroscience with targeted investments in opportunities and collaborations.
Our business strategy sets out our path to success in delivering great medicines to patients through innovative science and global excellence in development and commercialisation.
Alongside our own research and development, we continue to partner with others to access the best science and accelerate the delivery of new medicines. We have been active in building early stage biotech and academic alliances in recent years and we want to do more of these, alongside in-licensing and acquisitions to strengthen our pipeline and broaden the range of treatment options for physicians and patients.
More broadly, collaboration is part of everyday business for us. Understanding the needs of patients and healthcare professionals, and the perspectives of regulators and those who pay for healthcare, is critical to our continued success. We work closely with these groups to get the insights we need to deliver distinctive, targeted medicines that make a difference in healthcare.
Across all our activity, we are committed to driving business success responsibly, acting with integrity and working to high ethical standards to maintain the trust of our stakeholders.
Improving health is one of the toughest challenges facing the world today and it will take a sustained and significant effort to drive continued progress. AstraZeneca has a key contribution to make to that effort.